Rasche M, Zimmermann M, Borschel L, Bourquin J, Dworzak M, Klingebiel T, et al. Successes and challenges within the therapy of pediatric acute myeloid leukemia: a retrospective evaluation of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167–77.
Manola KN. Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol. 2009;83:391–405.
Stark B, Jeison M, Gabay LG, Mardoukh J, Luria D, Bar-Am I, et al. Classical and molecular cytogenetic abnormalities and consequence of childhood acute myeloid leukaemia: report from a referral centre in Israel. Br J Haematol. 2004;126:320–37.
Quessada J, Cuccuini W, Saultier P, Loosveld M, Harrison CJ, Lafage-Pochitaloff M. Cytogenetics of pediatric acute myeloid leukemia: a evaluate of the present data. Genes. 2021;12:924.
Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. Writer correction: The molecular panorama of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2019;25:530.
Nguyen-Khac F, Bidet A, Veronese L, Daudignon A, Penther D, Troadec M, et al. Suggestions for cytogenomic evaluation of hematologic malignancies: feedback from the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia. 2020;34:1711–3.
Duncavage EJ, Schroeder MC, O’Laughlin M, Wilson R, MacMillan S, Bohannon A, et al. Genome sequencing as a substitute for cytogenetic evaluation in myeloid cancers. N Engl J Med. 2021;384:924–35.
Rack KA, van den Berg E, Haferlach C, Beverloo HB, Costa D, Espinet B, et al. European suggestions and high quality assurance for cytogenomic evaluation of haematological neoplasms. Leukemia. 2019;33:1851–67.
Rack KA, van den Berg E, Haferlach C, Beverloo HB, Costa D, Espinet B, et al. European suggestions and high quality assurance for cytogenomic evaluation of haematological neoplasms: reponse to the feedback from the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia. 2020;34:2262–4.
Gindin T, Hsiao SJ. Analytical ideas of most cancers subsequent era sequencing. Clin Lab Med. 2022;42:395–408.
Illumina. Native Run Supervisor RNA Fusion: Workflow Information; 2018. https://help.illumina.com/content material/dam/illumina-support/paperwork/documentation/software_documentation/local-run-manager/local-run-manager-rna-fusion-workflow-guide-1000000010786-02.pdf.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast common RNA-seq aligner. Bioinformatics. 2013;29:15–21.
Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, et al. Manta: fast detection of structural variants and indels for germline and most cancers sequencing functions. Bioinformatics. 2016;32:1220–2.
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Prognosis and administration of acute myeloid leukemia in kids and adolescents: suggestions from a world knowledgeable panel. Blood. 2012;120:3187–205.
Schlegelberger B, Metzke S, Tougher S, Zühlke-Jenisch R, Zhang Y, Siebert R. Classical and molecular cytogenetics of tumor cells. In: Wegner, RD editors. Diagnostic cytogenetics. Springer Lab Guide. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59918-7_9.
Bustin SA. Absolute quantification of mRNA utilizing real-time reverse transcription polymerase chain response assays. J Mol Endocrinol. 2000;25:169–93.
Heid CA, Stevens J, Livak KJ, Williams PM. Actual time quantitative PCR. Genome Res. 1996;6:986–94.
Suttorp J, Lühmann JL, Behrens YL, Göhring G, Steinemann D, Reinhardt D, et al. Optical genome mapping as a diagnostic device in pediatric acute myeloid leukemia. Cancers. 2022;14:2058.
Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a device to design target-specific primers for polymerase chain response. BMC Bioinform. 2012;13:134.
Gröschel, Sanders S, Hoogenboezem MA, Wit R, de E, Bouwman BAM, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369–81.
Suzukawa Okay, Parganas E, Gajjar A, Abe T, Takahashi S, Tani Okay, et al. Identification of a breakpoint cluster area 3’ of the ribophorin I gene at 3q21 related to the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood. 1994;84:2681–8.
Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, et al. A distant GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Most cancers Cell. 2014;25:415–27.
Gabert J, Beillard E, Van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and high quality management research of ‘real-time’ quantitative reverse transcriptase polymerase chain response of fusion gene transcripts for residual illness detection in leukemia – a Europe Towards Most cancers program. Leukemia. 2003;17:2318–57.
Beillard E, Pallisgaard N, Van der Velden VHJ, Bi W, Dee R, van der Schoot E, et al. Analysis of candidate management genes for prognosis and residual illness detection in leukemic sufferers utilizing ‘real-time’ quantitative reverse-transcriptase polymerase chain response (RQ-PCR) – a Europe in opposition to most cancers program. Leukemia. 2003;17:2474–86.
Espersen ADL, Noren-Nyström U, Abrahamsson J, Ha S, Pronk CJ, Jahnukainen Okay, et al. Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is related to infancy and trisomy 19: Knowledge from Nordic Society for Pediatric Hematology and Oncology (NOPHO-AML) and evaluate of the literature. Genes Chromosomes Most cancers. 2018;57:359–65.
Ragusa D, Dijkhuis L, Pina C, Tosi S. Mechanisms related to t(7;12) acute myeloid leukaemia: from genetics to potential therapy targets. Biosci Rep. 2023;43:BSR20220489.
von Bergh AR, van Drunen E, van Wering ER, van Zutven LJ, Hainmann I, Lönnerholm G, et al. Excessive incidence of t(7;12)(q36;p13) in toddler AML however not in toddler ALL, with a dismal consequence and ectopic expression of HLXB9. Genes Chromosomes Most cancers. 2006;45:731–9.
Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, et al. CBFA2T3-GLIS2 fusion transcript is a novel frequent function in pediatric, cytogenetically regular AML, not restricted to FAB M7 subtype. Blood. 2013;121:3469–72.
Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a definite HOX gene expression sample. Blood. 2011;118:3645–56.
Peterson JF, Sukov WR, Pitel BA, Smoley SA, Pearce KE, Meyer RG, et al. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year expertise from a single genomics laboratory. Genes Chromosomes Most cancers. 2019;58:567–77.
Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988–1005.
Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: outcomes of a world retrospective examine. Blood. 2009;114:2489–96.
Hoffmeister LM, Orhan E, Walter C, Niktoreh N, Hanenberg H, Neuhoff NV, et al. Influence of KMT2A rearrangement and CSPG4 expression in pediatric acute myeloid leukemia. Cancers. 2021;13:4817.
Rasche M, Zimmermann M, Steidel E, Alonzo T, Aplenc R, Bourquin J, et al. Survival following relapse in kids with acute myeloid leukemia: a report from AML-BFM and COG. Cancers. 2021;13:2336.
Reinhardt D, Antoniou E, Waack Okay. Pediatric acute myeloid leukemia-past, current, and future. J Clin Med. 2022;11:504.
Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo HB, et al. Integrative evaluation of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011;96:1478–87.
Ries RE, Leonti AR, Triche TJ, Gerbing RB, Hirsch BA, Raimondi SC, et al. Structural variants involving MLLT10/AF10 are related to adversarial consequence in AML whatever the accomplice gene – a COG/Tpaml examine. Blood. 2019;134:461.
Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, et al. Complete molecular and scientific characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108:2044–58.
Katsumoto T, Yoshida N, Kitabayashi I. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in regular and malignant hematopoiesis. Most cancers Sci. 2008;99:1523–7.
Conneely SE, Stevens AM. Acute myeloid leukemia in kids: rising paradigms in genetics and new approaches to remedy. Curr Oncol Rep. 2021;23:16.
Martelli MP, Rossi R, Venanzi A, Meggendorfer M, Perriello VM, Martino G, et al. Novel NPM1 exon 5 mutations and gene fusions resulting in aberrant cytoplasmic nucleophosmin in AML. Blood. 2021;138:2696–701.
Belloni E, Shing D, Tapinassi C, Viale A, Mancuso P, Malazzi O, et al. In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia within the presence of GATA1 lowered ranges. Leukemia. 2011;25:733–6.
Kovach AE, Zerkalenkova E, Zemtsova L, Borkovskaya A, Gaskova M, Kazanov M. et al. Acute myeloid leukemia with t(X;6)9p11;q23);MYB-GATA1 and feminine intercourse: GATA1 insufficiency could also be inadequate for pathogenesis. Most cancers Genet.2022;260–261:37–40.
Ozono S, Yano S, Oishi S, Mitsuo M, Nakagawa S, Toki T, et al. A case of congenital leukemia with MYB-GATA1 fusion gene in a feminine affected person. J Pediatr Hematol Oncol. 2022;44:e250–e252.
Quelen C, Lippert E, Struski S, Demur C, Soler G, Prade N, et al. Identification of a reworking MYB-GATA1 fusion gene in acute basophilic leukemia: a brand new entity in male infants. Blood. 2011;117:5719–22.
Shiba N, Yoshida Okay, Hara Y, Yamato G, Shiraishi Y, Matsuo H, et al. Transcriptome evaluation provides a complete illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv. 2019;3:3157–69.
Yanagisawa R, Kato M, Sakaguchi Okay, Nakagoshi R, Ogiso Y, Fukushima Okay, et al. A case of pure erythroid leukemia with MYB-GATA1 fusion that developed tumor lysis syndrome with dexamethasone. Pediatr Blood Most cancers. 2020;67:e28285.
Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already information remedy decision-making? Hematol Am Soc Hematol Educ Program. 2016;2016:356–65.
Pigazzi M, Manara E, Buldini B, Beqiri V, Bisio V, Tregnago C, et al. Minimal residual illness monitored after induction remedy by RQ-PCR can contribute to tailor therapy of sufferers with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica. 2015;100:e99–101.
